Aerosolized iloprost induces a mild but sustained inhibition of platelet aggregation

BEGHETTI, Maurice, et al.

Abstract
Pathological studies have revealed that one of the main features encountered in the pulmonary vasculature of patients with pulmonary hypertension is the presence of thrombotic lesions. Open pilot studies have indicated that aerosolized iloprost may have beneficial effects in patients with pulmonary hypertension. The effects of aerosolized iloprost on platelet function and plasma cyclic adenosine monophosphate (cAMP) were studied. Platelet aggregation and plasma cAMP were measured at baseline, 30 min, 4 and 6 h after inhalation of 15 microg iloprost in 10 healthy volunteers. Maximal platelet aggregation in response to adenosine diphosphate (ADP) (2 and 6 micromol x L(-1)), collagen (2.5 and 5 microg x mL(-1)), epinephrine (1.25 and 5 micromol x L(-1)) and arachidonic acid (0.5 mg x mL(-1)) was measured. Platelet aggregation was significantly inhibited at 30 min in response to ADP (2 and 6 micromol x L(-1)), collagen (2.5 and 5 micromol x L(-1)) and epinephrine (1.25 and 5 micromol x L(-1)) and collagen (2.5 micromol x mL(-1)). It was still inhibited at 4 h in response to the same agents, but normalized at 6 h. cAMP increased at 30 min, from 27.3+/-1.2 to 31.8+/-1.2 [...]
Aerosolized iloprost induces a mild but sustained inhibition of platelet aggregation

M. Beghetti*, G. Reber¹, P. de Moerloose¹, L. Vadas*, A. Chiappe*, I. Spahr-Schopfer†, P.C. Rimensberger§


ABSTRACT: Pathological studies have revealed that one of the main features encountered in the pulmonary vasculature of patients with pulmonary hypertension is the presence of thrombotic lesions. Open pilot studies have indicated that aerosolized iloprost may have beneficial effects in patients with pulmonary hypertension. The effects of aerosolized iloprost on platelet function and plasma cyclic adenosine monophosphate (cAMP) were studied.

Platelet aggregation and plasma cAMP were measured at baseline, 30 min, 4 and 6 h after inhalation of 15 μg iloprost in 10 healthy volunteers. Maximal platelet aggregation in response to adenosine diphosphate (ADP) (2 and 6 μmol L⁻¹), collagen (2.5 and 5 μg mL⁻¹), epinephrine (1.25 and 5 μmol L⁻¹) and arachidonic acid (0.5 mg mL⁻¹) was measured.

Platelet aggregation was significantly inhibited at 30 min in response to ADP (2 and 6 μmol L⁻¹), epinephrine (1.25 and 5 μmol L⁻¹) and collagen (2.5 μg mL⁻¹). It was still inhibited at 4 h in response to the same agents, but normalized at 6 h. CAMP increased after inhalation of iloprost in 10 healthy volunteers. Maximal platelet aggregation was measured.

Platelet aggregation was significantly inhibited at 30 min in response to ADP (2 and 6 μmol L⁻¹), epinephrine (1.25 and 5 μmol L⁻¹) and collagen (2.5 μg mL⁻¹). It was still inhibited at 4 h in response to the same agents, but normalized at 6 h.

Aerosolized iloprost induced a mild but sustained inhibition of platelet aggregation. Platelet aggregation inhibition may be one of the mechanisms which explains the beneficial effect of repeated inhalation of iloprost in pulmonary hypertension.

Methods

Subjects

Institutional ethics committee approval and informed consent were obtained prior to recruiting 10 healthy adult volunteers (six males, four females), aged 26–53 yrs (mean ± SEM age; 40 ± 2 yrs), to participate in the study. None of the subjects had taken aspirin or other medication known to affect platelet function in the 3 weeks before the study.

Design

The study was conducted in the haemostasis laboratory to perform platelet function tests immediately after sampling. On arrival in the laboratory, subjects were asked to rest for 10 min. They were sitting comfortably during inhalation. At baseline and 30 min, 4 and 6 h following inhalation, blood sampling for platelet function tests and plasma cAMP measurements were performed. Transcutaneous oxygen saturation (Nellcor pulse oximeter N-180 finger probe; Nellcor N200 oxygen saturation monitor, Nellcor, Garbamed Libefeld, Switzerland) was monitored continuously during inhalation. Cuff blood pressure, on the opposite arm of blood sampling, was measured every 5 min during inhalation, and 30 min, 4 and 6 h after inhalation. Heart and respiratory rate were also recorded following the same schedule.

Administration of iloprost aerosol

Iloprost (Ilomedin, Schering Schweiz AC, Schlieren, Switzerland) was prepared from a vial of 50 μg·0.5 mL⁻¹ diluted in 4.5 mL of 0.9% NaCl, to obtain a solution of 10 μg·mL⁻¹. A concentration of 15 μg in a 3 mL volume was obtained from 1.5 mL of the solution and 1.5 mL of NaCl 0.9%, and then placed in the nebulizing chamber. All aerosols were generated by a jet nebulizer Pari LL (PARI GmbH, Starnberg, Germany), allowing nebulization only during inspiration, driven by a PARI Master air compressor (PARI GmbH). This device produces particles with a mass median aerodynamic diameter of 2.8 μm with >80% of the particles measuring <3 μm. The subjects were instructed to inhale through a mouthpiece at 5–10 breath-min⁻¹ with tidal volume respiration over 10 min.

Placebo-controlled group

Following the same design, four out of the 10 volunteers (three male and one female, mean ± SEM age: 43 ± 5 yrs) were used as controls too, by inhaling 3 mL normal saline (NaCl 0.9%) to obtain placebo-controlled data.

Blood sampling

Blood was collected from an antecubital vein using a vacutainer technique. The first 3 mL of blood were collected in an ethylenediamine tetra-acetic acid vacutainer (Becton Dickinson Vacutainer systems Europe, Meylan, France) and processed for cAMP measurements, haemoglobin and platelet count (Sysmex K1000, Toa, Japan). The following 15 mL were collected in tubes anticoagulated with sodium citrate 0.129 M (1 in 10) (Becton Dickinson Vacutainer systems Europe) for platelet function studies.

Platelet function studies

Platelet-rich plasma was obtained by low-speed centrifugation and brought to 300 g·L⁻¹ with platelet-poor plasma. Aggregation was performed with a PAP-4 aggregometer (Bio Data, Horsham, PA, USA). It allows a photometric recording of platelet aggregation, based upon changes in platelets dispersed in a plasma environment when challenged with different agonists. The agonists were: 1) 2 and 6 μmol·L⁻¹ adenosine diphosphate (ADP); 2) 1.25 and 5 μmol·L⁻¹ epinephrine; 3) 0.5 mg·mL⁻¹ arachidonic acid; and 4) 2.5 and 5 μg·mL⁻¹ collagen. The platelet aggregometer was tested first with platelet-poor plasma to set the 100% baseline, and with nonstimulated platelet-rich plasma to set the 0% baseline. Interpretation of aggregation and thus of platelet function was based on the maximal percentage of aggregation at 5 min.

Platelet function was investigated also by measuring the closure time of epinephrine or ADP collagen-coated membranes with the Platelet Function Analyser PFA100 (Dade Behring, Düdingen, Switzerland). The PFA-100 is an instrument and test cartridge system in which the process of platelet adhesion and aggregation following a vascular injury is simulated in vitro [14]. Reference normal ranges for the study laboratory are 71–118 s for ADP and 93–194 s for epinephrine.

Cyclic adenosine monophosphate measurements

Plasma was obtained by immediate centrifugation at 1,600xg for 10 min at 4°C, and then stored at -70°C until analysis. cAMP levels were determined in batches using a commercial solid phase radioimmunoassay kit (Immunotech, Biffilman laboratories AG, Basel, Switzerland). The assay has a measurement range of 5–50 nmol·L⁻¹ with a sensitivity of 0.2 nmol·L⁻¹.

Statistical analysis

Mean and median, 75th and 25th percentile, standard deviation (SD) and standard error of the mean (SEM) were calculated for all parameters. Results are expressed as mean ± SEM unless otherwise indicated. For each parameter, analysis of variance (ANOVA) for normally distributed data or the Friedman’s test for data not normally distributed, were used for repeated measurements, with post hoc corrections, as appropriate, for all pairwise multiple comparisons (Tukey’s or Dunn multiple comparison test). A value
Table 1. – Maximal aggregation (%) and platelet function analyser (PFA) closure time in response to the different agonists before and after inhalation of iloprost

<table>
<thead>
<tr>
<th>Maximal aggregation %</th>
<th>Baseline</th>
<th>30 min</th>
<th>4 h</th>
<th>6 h</th>
<th>p-value#</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADP 2 μM</td>
<td>47.3±9.1</td>
<td>20.2±8.9*</td>
<td>35.8±8.6*</td>
<td>41.6±9.2</td>
<td>0.005</td>
</tr>
<tr>
<td>ADP 6 μM</td>
<td>73.2±4.2</td>
<td>60.1±4.5*</td>
<td>61.6±6.2*</td>
<td>63.1±5.1</td>
<td>0.01</td>
</tr>
<tr>
<td>EPI 1.25 μM</td>
<td>49.3±9.1</td>
<td>33.9±9.3*</td>
<td>37.1±10.4*</td>
<td>41.5±8.9</td>
<td>0.009</td>
</tr>
<tr>
<td>EPI 5 μM</td>
<td>75.8±3</td>
<td>58.6±6.1*</td>
<td>55.7±3.5*</td>
<td>65.9±6.1</td>
<td>0.01</td>
</tr>
<tr>
<td>Coll 2.5 μg·mL⁻¹</td>
<td>80±2.2</td>
<td>70.3±3.7*</td>
<td>77.6±2.3</td>
<td>76.3±3.5</td>
<td>0.04</td>
</tr>
<tr>
<td>Coll 5 μg·mL⁻¹</td>
<td>79.5±2.2</td>
<td>76.8±2.4</td>
<td>72.8±4.6</td>
<td>78.9±2.3</td>
<td>0.22</td>
</tr>
<tr>
<td>AA 0.5 mg·mL⁻¹</td>
<td>76±3.3</td>
<td>64.3±6.5</td>
<td>61.9±7.2</td>
<td>71.3±3.1</td>
<td>0.05</td>
</tr>
<tr>
<td>PFA closure time s</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPI</td>
<td>168.6±19</td>
<td>188.3±21.3</td>
<td>194.6±22.1</td>
<td>192.7±23</td>
<td>0.38</td>
</tr>
<tr>
<td>ADP</td>
<td>79.8±6.3</td>
<td>81.5±6</td>
<td>89.3±3.5</td>
<td>89.7±5.4</td>
<td>0.08</td>
</tr>
</tbody>
</table>

Data are presented as mean±SEM unless otherwise stated. ADP: adenosine diphosphate; EPI: epinephrine; Coll: collagen; AA: arachidonic acid. # p-value as determined by analysis of variance; * p<0.05.

Table 2. – Maximal aggregation (%) and platelet function analyser (PFA) closure time in response to the different agonists before, and after inhalation of placebo

<table>
<thead>
<tr>
<th>Maximal aggregation %</th>
<th>Baseline</th>
<th>30 min</th>
<th>4 h</th>
<th>6 h</th>
<th>ANOVA</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADP 2 μM</td>
<td>46.2±12.4</td>
<td>42.5±9.5</td>
<td>39.3±12.5</td>
<td>41.3±4.2</td>
<td>NS</td>
</tr>
<tr>
<td>ADP 6 μM</td>
<td>69.1±6.9</td>
<td>83.8±5.9</td>
<td>71.6±8.7</td>
<td>82.3±5.6</td>
<td>NS</td>
</tr>
<tr>
<td>EPI 1.25 μM</td>
<td>43.3±6.2</td>
<td>40.8±12.4</td>
<td>48.2–10.9</td>
<td>43.3±15.1</td>
<td>NS</td>
</tr>
<tr>
<td>EPI 5 μM</td>
<td>53.1±11</td>
<td>62.9±14.3</td>
<td>52.1±13.3</td>
<td>62.8±13.1</td>
<td>NS</td>
</tr>
<tr>
<td>Coll 2.5 μg·mL⁻¹</td>
<td>84.3±8.6</td>
<td>89.1±6.2</td>
<td>84.6±6</td>
<td>95±7</td>
<td>NS</td>
</tr>
<tr>
<td>Coll 5 μg·mL⁻¹</td>
<td>70.4±5.2</td>
<td>92.3±6.7</td>
<td>81±43.7</td>
<td>92.8±6.8</td>
<td>NS</td>
</tr>
<tr>
<td>AA 0.5 mg·mL⁻¹</td>
<td>53.9±8.4</td>
<td>66.1±4.2</td>
<td>59.7±73.4</td>
<td>85.1±9</td>
<td>NS</td>
</tr>
<tr>
<td>PFA closure time s</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPI</td>
<td>135.5±6</td>
<td>154.8±20</td>
<td>171.3±18</td>
<td>157±25</td>
<td>NS</td>
</tr>
<tr>
<td>ADP</td>
<td>90±4</td>
<td>81.5±7.1</td>
<td>86.5±9.7</td>
<td>92±5.3</td>
<td>NS</td>
</tr>
</tbody>
</table>

Data are presented as mean±SEM unless otherwise stated. ANOVA: analysis of variance; ADP: adenosine diphosphate; EPI: epinephrine; Coll: collagen; AA: arachidonic acid; NS: nonsignificant.

of p<0.05 was considered to indicate statistical significance.

Results

Platelet function studies

Maximal aggregation in response to the different agonists and platelet function analyser (PFA) closure time before, during and after inhalation are presented in table 1. Platelet aggregation was significantly inhibited at 30 min in response to 2 and 6 μmol·L⁻¹ ADP, 1.25 and 5 μmol·L⁻¹ epinephrine and 2.5 μg·mL⁻¹ collagen. It was still inhibited at 4 h with the same agents, except collagen, and normalized at 6 h. PFA closure times for ADP and epinephrine did not change significantly at any time (table 1). No changes in platelet aggregation or PFA closure times were observed in the placebo-controlled group (table 2).

Plasma cyclic adenosine monophosphate concentrations

The basal plasma cAMP level was 27.3±1.3 nmol·L⁻¹. cAMP increased (31.8±1.2 nmol·L⁻¹; p<0.001) 30 min after the beginning of iloprost inhalation, remained slightly elevated 4 h after inhalation (29.2±1.3 nmol·L⁻¹; p<0.05 versus baseline) and normalized completely at 6 h (27.4±1.1 nmol·L⁻¹; nonsignificant versus baseline, but p<0.001 versus 30 min) (fig. 1). Plasma cAMP levels did not change extend down to the minimal and up to the maximal values.

Fig. 1. – Plasma cyclic adenosine monophosphate levels before and after iloprost inhalation, remained slightly elevated 4 h after inhalation, and normalized completely at 6 h (27.4±1.1 nmol·L⁻¹; nonsignificant versus baseline, but p<0.001 versus 30 min).
in the placebo-controlled group (22.7±2.5 nmol·L⁻¹ at baseline, 21.1±1.4 nmol·L⁻¹ at 30 min, 21.9±1.9 nmol·L⁻¹ at 4 h and 22.1±1.2 nmol·L⁻¹ at 6 h).

**Effects on blood pressure and transcutaneous oxygen saturation**

Changes in blood pressure, heart rate and transcutaneous oxygen saturation are described in tables 3 and 4. A small but significant decrease in systolic, diastolic and mean blood pressure was observed during iloprost inhalation. Blood pressure returned to baseline values at 4 and 6 h after inhalation. Cardiac frequency increased significantly during inhalation and returned to baseline immediately after. Transcutaneous oxygen saturation also showed an increase during inhalation.

Except for transient headaches and facial flush in two subjects, no adverse events were observed. There were no changes in any of the variables in the placebo-controlled group.

**Discussion**

These results show that aerosolized iloprost induces a mild but sustained inhibition of platelet aggregation in systemic venous blood. This effect seems to be mediated, as it occurs with endogenous PGI₂, through an increase in cAMP.

Intravenous administration of iloprost in human volunteers [15] and patients with peripheral arterial occlusive disease [16] or angina pectoris [17] induces an inhibition of platelet aggregation in response to the same agonists as those used in the present study. The results shown here also indicate that it inhibits platelet aggregation when administered by inhalation. 

[BURGHUBER et al. ] [18] showed that PGI₂ administered by inhalation caused an inhibition of ADP-induced platelet aggregation. Although a small-acting substance PGI₂ was used in their patients, and the effect was still present 30 min after the end of inhalation. With iloprost, inhibition of platelet aggregation seems even more prolonged due to its longer half-life. In this study, the effect on platelets is mild but prolonged as it is still present 4 h after inhalation. The clinical effects of iloprost administered by inhalation, based on the effect on pulmonary arterial pressure, is estimated at 60–120 min [8], but it has been shown that the platelet inhibition may last longer than vasodilation [19]. A continuous release of iloprost after deposition in the lungs may be an explanation of this long-lasting inhibition of platelet aggregation, but this question cannot be answered by the present study. Objective markers of systemic platelet effects disappear 6 h after iloprost inhalation. This needs to be remembered as most of the patients treated with inhaled iloprost in clinical studies do not inhale their drugs at night. This may lead to a lack of efficacy in the morning. This may be detrimental to the patient. Approaches leading to prolonged iloprost effects, such as the use of phosphodiesterase inhibitors, may be of value [20].

The inhibition of platelet aggregation induced by inhaled iloprost in this study has to be considered as a mild effect, as it is more pronounced with the lowest doses of ADP, epinephrine and collagen, and not present with arachidonic acid which is considered to be the most potent of these agonists. In addition, the indirect assessment of bleeding time, through the measurements of PFA closure time, shows that the potential risk of bleeding remains low. Similar results were obtained with PGI₂ in a study by van HEERDEN et al. [21], where they found inhibition of platelet aggregation using platelet aggregometry in response to ADP and collagen, but the thromboelastogram remained normal. No episodes of bleeding have been reported so far with the use of inhaled PGI₂ or iloprost. However, the use of this therapy in patients with a risk of bleeding, such as postcardiopulmonary

| Table 4. – Blood pressure, heart rate and transcutaneous oxygen saturation before, during and after inhalation of placebo |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                 | Baseline | 5 min | 10 min | 15 min | 30 min | 4 h | 6 h | p-value
| SBP mmHg | 109±5     | 110±5     | 108±4     | 107±4     | 111±7     | 111±7     | 114±8 | NS        |
| DBP mmHg | 70±5      | 70±5      | 72±7      | 72±8      | 68±8      | 66±7      | 70±7  | NS        |
| MBP mmHg | 77±6      | 78±8      | 80±7      | 78±6      | 76±6      | 71±6      | 75±4  | NS        |
| HR beats·min⁻¹ | 67±7     | 66±6     | 66±4     | 64±5     | 63±7     | 70±8     | 65±6  | NS        |
| Saturation %  | 97±0.9   | 98±3.1   | 98.8±1   | 98.8±0.6   | 97.0±4   | 98±0.5   | 98±0.3 | NS        |

Data are presented as mean±SEM. SBP: systolic blood pressure; DBP: diastolic blood pressure; MBP: mean blood pressure; HR: heart rate; NS: nonsignificant. #: repeated measures analysis of variance.
bypass patients with pulmonary hypertension [22], or particularly sensitive to the risk of bleeding, such as newborns or premature babies with pulmonary hypertension [23] may not be justified yet.

An increase in cAMP was associated with the inhibition of platelet aggregation. Most of the biological effects of iloprost are thought to be related to an intracellular increase of cAMP. In this study cAMP increased by 17%; an early greater increase may have been missed as this level was measured 30 min after inhalation. However, plasma cAMP levels may not reflect the intraplatelets increase and this may explain the relatively low increase in cAMP. HARDY et al. [24] showed that, with PGI\(_2\), a peak in cAMP appears at 5 min and then stabilizes to a lower baseline at 10 min which remains increased for 45 min. This long-lasting increase in cAMP, which is even more marked in the present study using inhaled iloprost, may explain the prolonged effect on platelet aggregation. Based on the results presented in this study, the inhibition of platelet aggregation associated with an increase in plasma cAMP levels, is believed to indicate a systemic absorption of iloprost during inhalation. This is confirmed by the slight decrease in blood pressure, especially the diastolic pressure, which may reflect a decrease in systemic vascular resistance. The appearance of facial flush and headaches in two subjects are characteristic signs observed with intravenous administration [25] and confirm a systemic spillover. In addition, similar effects were observed by HOEPER et al. [13] in patients treated with aerosolized iloprost.

There is evidence that intravascular coagulation in the pulmonary circulation may be a continuous process in pulmonary hypertension [26]. Moreover, platelet [7, 27] and plasma coagulation profile abnormalities [28] have been reported in patients with primary and secondary pulmonary hypertension, and the effect of oral anticoagulation has proven to be beneficial on survival [29]. Recently, studies analysing markers of platelet activation suggested that platelets of patients with pulmonary hypertension are not activated, but had an accelerated turnover and returned to normal after epoprostenol therapy [30]. An increase in the release of the vasoconstrictor, thromboxane A\(_2\) has been shown suggesting the activation of platelets occurs in both the primary and secondary forms of pulmonary hypertension [31]. In addition, the release of PGI\(_2\) is decreased in the same patients. TUDER et al. [32] showed that expression of PGI\(_2\) synthase was depressed in lungs from patients with pulmonary hypertension. Decreased PGI\(_2\) production might predispose patients to vasoconstriction and thrombosis in situ. This explains why aspirin, a well known antiplatelet drug is not used in pulmonary hypertension to prevent thrombosis. Aspirin has cyclooxygenase inhibitory effects that may aggravate pulmonary hypertension through the inhibition of endogenous prostaglandin production [33]. Continuous infusion of PGI\(_2\) results in clinical and haemodynamic improvement in patients with pulmonary hypertension and seems to be beneficial to endothelial function [34]. It has also been shown that continuous infusion of PGI\(_2\) decreases plasma levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in primary pulmonary hypertension [35]. It has even been suggested that the activation of smooth muscle cell proliferation is the consequence of platelet aggregation on vessel walls [26]. Activation of platelets in pulmonary hypertension may not only induce local thrombosis but may contribute to vascular remodelling through the release of platelet-selective mediators such as thromboxane A\(_2\), serotonin and growth factors [36]. All these findings prove that the platelet plays an important role in the pathophysiology of pulmonary hypertension. The antiplatelet effect observed in this study supports the use of inhaled iloprost and may explain in part the clinical improvement obtained with daily repetitive inhalations in patients with primary and secondary pulmonary hypertension.

This study shows some limitations. A dose-dependent effect has been demonstrated with intravenous administration of iloprost, but this was not evaluated in this study since only a single dose was given [2, 11, 15, 21]. Dose-response curves would have been of benefit in order to compare the dose-dependent effect obtained with the intravenous administration. Higher doses of inhaled iloprost may have more pronounced systemic haemodynamic effects, such as hypotension, which would not be of benefit. However, 15 μg does represent the mean dose used in clinical studies and therefore can be considered as representative. The exact dose delivered can only be estimated and is related to the nebulizer capacities. Although only little is known on particle size and lung distribution, the demonstration of changes in platelet aggregation, cAMP and systemic pressure provide proof of the effective drug delivery. Intraplatelet cAMP was not measured to confirm the activation of platelet adenylate cyclase, but based on in vitro experiments with iloprost, one can assume that this was the pathway leading to inhibition of platelet aggregation in this study [2]. The results show that the potentially beneficial effect on platelet function, obtained with continuous, intravenous prostacyclin infusion, may also be obtained with aerosolized iloprost. Considering the decreased prostacyclin and increased thromboxane A\(_2\) production, and the presence of microthrombi in peripheral lung vessels of patients with pulmonary hypertension, these results may explain in part the observed long-term effect of repetitive inhalation of iloprost in pulmonary hypertension. Further studies are required to confirm this effect in patients with pulmonary hypertension.

Acknowledgements. The authors would like to thank Schering AG, Zurich, Switzerland for providing iloprost.

References

1. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that


